



# NON-ODONTOGENIC TOOTHACHE

**Ramesh Balasubramaniam OAM**

**DENT5310**

**Orofacial Pain and Dental Sleep Medicine Module**

**24<sup>th</sup> April 2026**



**Ramesh Balasubramaniam OAM**  
**Associate Professor**  
**Discipline Lead in Oral Medicine**  
**UWA Dental School**  
**The University of Western Australia**



**Neither I nor my immediate family have any financial interests that would create a conflict of interest or restrict my independent judgment with regard to the content of this presentation.**



**ODONTOGENIC PAINS**

**SITE VS SOURCE OF OROFACIAL PAIN**

**NON-ODONTOGENIC PAINS**

**TAKE HOME MESSAGE**



**ODONTOGENIC PAINS**


**SITE VS SOURCE OF OROFACIAL PAIN**

**NON-ODONTOGENIC PAINS**

**TAKE HOME MESSAGE**


## The multiple 'faces' of toothache

Odontogenic pain originates from the teeth, dental pulp, periodontal ligaments, or surrounding structures like the alveolar bone.



**"There was never yet philosopher that could endure the toothache patiently"**  
William Shakespeare -  
"Much Ado About Nothing"

# ODONTOGENIC PAINS FACTS





**ODONTOGENIC PAINS**

**SITE VS SOURCE OF OROFACIAL PAIN**

**NON-ODONTOGENIC PAINS**

**TAKE HOME MESSAGE**



## Site of Pain

- The location where the patient feels the pain



## Source of Pain

- That tissue from which the pain actually originates

# SITE VS SOURCE OF PAIN

## Primary Pain


- Site (where it hurts) = Source (where it originates)

## Heterotopic Pain

- Site  $\neq$  Source
- Projected Pain or Referred Pain

**Treatment Success is achieved by  
treating the Source of Pain,  
NOT the Site of Pain**

# SITE VS SOURCE OF PAIN





**ODONTOGENIC PAINS**

**SITE VS SOURCE OF OROFACIAL PAIN**

**NON-ODONTOGENIC PAINS**

**TAKE HOME MESSAGE**

# NON-ODONTOGENIC PAINS




Non-odontogenic pain refers to pain in the orofacial region (mouth, teeth, jaw, and face) that originates from sources other than the teeth or their supporting structures.

Greater incidence  
molars >  
premolars >  
incisors

Maxillary >  
Mandibular  
Teeth


2.5-4%: dental  
visits for  
"toothache"




10%:  
concomitant  
odontogenic  
causes

Most prevalent  
between 2<sup>nd</sup> &  
6<sup>th</sup> decade

# NON-ODONTOGENIC PAINS



# NON-ODONTOGENIC PAINS



# MYOFASCIAL ORIGIN

**Non-Odontogenic Pain of Myofascial Origin refers to pain originating from muscles and fascia that present as tooth pain**

Active trigger point: localised hyperexcitable nodule (neuromuscular dysfunction at the motor endplate)


## TRIGGER POINT

Taut band of skeletal muscle

A firm nodule that is tender to palpation will refer pain to a distant site 80% of the time

Convergence Theory: trigeminal sensory complex

# MYOFASCIAL ORIGIN: CLINICAL PRESENTATION



Quality

- Dull, ache
- Constant

No obvious dental signs of pathology

- Negative pulp test
- No clinical pathology
- No radiographic pathology

Muscle Provocation

- Palpation & Function of Source of Pain: Increases tooth pain


Trigger Point Injection

- Reduces / Relieves tooth pain
- Local anaesthetic of the tooth: no change to pain



# MYOFASCIAL ORIGIN: CLINICAL PRESENTATION









## NOT FUN FACTS!




11% of masticatory myofascial pain patients presented with non-odontogenic pain.

7% of "masticatory myofascial tooth pain" had unnecessary endodontic treatment.


# MYOFASCIAL ORIGIN: TRIGGER POINT



# MYOFASCIAL ORIGIN: TRIGGER POINT




# MYOFASCIAL ORIGIN: MANAGEMENT



Education & Reassurance



Pain-Free Jaw Function



Habit Awareness & Reversal




Spray & Stretch



Jaw Strengthening & Stretching Exercises



Physical Therapy



Trigger Point Injections



Oral Appliance Therapy



Pharmacotherapy




Botulinum Toxin Injections




Psychological Therapy

# NON-ODONTOGENIC PAINS




# PAIN OF NEUROVASCULAR ORIGIN

“Headache” may present as variant in the orofacial region mimicking toothache.



## NEUROVASCULAR OROFACIAL PAIN



# PAIN OF NEUROVASCULAR ORIGIN: CLINICAL PRESENTATION

Haviv Y. et al. J Oral Facial Pain Headache 2020;34(2):121-8.

**Duration: < 1 week**

- 1/3 chronic pain

**70% Unilateral**

- 62% alveolar process
- 32% mucosal sites

**Moderate – Severe  
Pulsating Pain**

- 35% woke patient

**F:M = 3.2:1**

- Age of onset:40 years

**Autonomic Features:**

- tearing
- nasal congestion
- rhinorrhoea
- fullness
- nausea
- photophobia
- phonophobia
- **DENTAL  
HYPERSENSITIVITY**



# PAIN OF NEUROVASCULAR ORIGIN: CLINICAL PRESENTATION

11 "lower-half facial migraine"



**NOT SO FUN FACTS!**



Time to  
diagnosis  
101 months  
(6 to 528  
months)

4:  
history of  
migraine

45%:  
endodontic  
treatment



36%: teeth  
extracted



# PAIN OF NEUROVASCULAR ORIGIN: CLINICAL PRESENTATION

X DONT NEGH TO  
KNOW

## Diagnostic Criteria for Neurovascular Orofacial Pain

**Description:** Attacks of variable duration of moderate or severe intraoral pain, without head pain, often accompanied by toothache-like symptoms, with mild autonomic and/or migrainous symptoms. Two subforms are represented by patients with relatively short attacks (1-4 hours) and those with longer attacks (>4 hours)

### Diagnostic criteria

A	<ul style="list-style-type: none"> <li>• At least five attacks of unilateral pain<sup>1</sup> of variable duration, without head pain, fulfilling criteria B-D</li> <li>• Recurrent paroxysms of the unilateral facial pain in the distribution(s) of one or more divisions of the trigeminal nerve, with no radiation beyond, and fulfilling criteria B and C</li> </ul>
B	<p>Pain has all of the following characteristics:</p> <ol style="list-style-type: none"> <li>1. Lasting from a fraction of a second to 2 minutes</li> <li>2. Moderate or severe intensity</li> <li>3. Electric shock-like, shooting, stabbing or sharp in quality</li> <li>4. Either or both of the following qualities:             <ol style="list-style-type: none"> <li>a) Toothache-like</li> <li>b) Pulsating</li> </ol> </li> </ol>
C	<ol style="list-style-type: none"> <li>1. Precipitated by innocuous stimuli within the affected trigeminal distribution</li> <li>2. Pain is accompanied by at least one of the following:             <ul style="list-style-type: none"> <li>• ipsilateral lacrimation and/or conjunctival injection</li> <li>• ipsilateral rhinorrhoea and/or nasal congestion</li> <li>• ipsilateral cheek swelling</li> <li>• photophobia and/or phonophobia</li> <li>• nausea and/or vomiting</li> </ul> </li> </ol>
D	Pain is unexplained by any local cause, and clinical and radiographic examinations are normal
E	Not better accounted by another ICOP or ICHD-3 diagnosis

# PAIN OF NEUROVASCULAR ORIGIN: MANAGEMENT

Benoliel R, Sharav Y, editors. Orofacial Pain and Headache: A Comprehensive Guide. 3rd ed. Newcastle upon Tyne: Cambridge Scholars Publishing; 2024.

Medical Status

```
graph TD; MS[Medical Status] --> P[Prophylactic]; MS --> A[Abortive]; P --> AM[Amitriptyline]; P --> PR[Propranolol]; P --> TP[Topiramate]; A --> TR[Triptans];
```

The diagram is a flowchart illustrating the management of neurovascular pain. It starts with 'Medical Status' at the top, which branches into 'Prophylactic' and 'Abortive'. 'Prophylactic' further branches into 'Amitriptyline', 'Propranolol', and 'Topiramate'. 'Abortive' branches into 'Triptans'. The background features a collage of green and white capsules.

Prophylactic

Abortive


Amitriptyline

Propranolol

Topiramate



Triptans

# NON-ODONTOGENIC PAINS



# PAIN OF SINUS ORIGIN

Orofacial pain of sinus origin refers to pain perceived in the face, jaws, or teeth that arises primarily from inflammatory, infectious, or obstructive pathology within the paranasal sinuses.



# PAIN OF SINUS ORIGIN

## CLINICAL PRESENTATION



Pressure or pain around the eyes, headache, halitosis, fatigue, cough, ear pain

- Nasal congestion, rhinorrhoea, purulent discharge, hyposmia/anosmia, fever, tenderness over sinus




Continuous dull ache of maxillary teeth

- Teeth sensitive to percussion, mastication, temperature (hyperalgesia)
- Maxillary posterior tooth pain: 9-11% of maxillary sinus infections



Toothache increased with lowering head

- Toothache increases with pressure applied over the sinus




Local anaesthesia of tooth does not eliminate the pain

### PATHOGENESIS:

Pain signals from diseased sinus mucosa are transmitted via the maxillary branch of trigeminal nerve (convergence), leading to pain that mimics odontogenic pain

# PAIN OF SINUS ORIGIN

## CLINICAL PRESENTATION




Acute left maxillary sinusitis manifesting as left-sided facial pain, left maxillary odontalgia, and purulent left-sided nasal discharge. Case 1 (a, b) – No odontogenic cause: the left maxillary sinus ostium and infundibulum of the ostiomeatal unit (common anterior sinus drainage channel) are occluded (white arrows in a) with dependent fluid, pneumatized secretions, and mucosal thickening in the sinus (open white arrow). No periapical or periodontal abnormality is seen (white dotted rectangle in b).

(Images courtesy of Clinical Associate Professor Andy Whyte, Perth Radiological Clinic, Perth WA, Australia)

# PAIN OF SINUS ORIGIN MANAGEMENT

90-98% of acute sinusitis cases are viral, with only 2-10% being bacterial

**NOT FUN FACTS!**



# PAIN OF SINUS ORIGIN MANAGEMENT

## Intranasal corticosteroid formulations for allergic rhinitis

Drug	Dose per spray	Initial dose for 4 weeks (into each nostril)	Maintenance dose
Beclometasone	50mcg	Adults: 2 sprays, twice daily Children 6 years and older: 1 to 2 sprays twice daily	1 spray twice daily
Budesonide	32mcg	Adults and children 6 years and older: 2 sprays twice daily, or 4 sprays once daily	1 to 2 sprays once daily
	64mcg	Adults and children 6 years and older: 1 spray twice daily, or 2 sprays once daily	1 spray once daily
Ciclesonide	50mcg	Adults and children 6 years and older: 2 sprays once daily	2 sprays once daily
Fluticasone furoate	27.5mcg	Adults: 2 sprays once daily Children 2 to 11 years: 1 to 2 sprays once daily	1 spray once daily
Fluticasone propionate	50mcg	Adults and children 12 years and older: 2 sprays once daily	1 spray once daily
Mometasone	50mcg	Adults: 2 sprays once daily Children 3 to 11 years: 1 spray once daily	1 spray once daily

\*Maintenance dose is the same for adults and children



# PAIN OF SINUS ORIGIN MANAGEMENT

Consider antibiotic therapy in addition to intranasal corticosteroids for patients who have any of the following indicators of bacterial infection:

- Symptoms of rhinosinusitis lasting longer than 7 days, with purulent nasal discharge, sinus tenderness (particularly unilateral) or maxillary toothache
- Severe symptoms and high fever (39°C or higher) at the onset of illness and lasting longer than 3 days
- Worsening symptoms after initial improvement ('double sickening')


# PAIN OF SINUS ORIGIN MANAGEMENT

- amoxicillin 500 mg (child: 15 mg/kg up to 500 mg) orally, 8-hourly for 5 days
- amoxicillin + clavulanate 500+125 mg (child: 22.5+3.2 mg/kg up to 500+125 mg) orally, 8-hourly for 7 to 14 days

## For Patients hypersensitive to Penicillins:

- cefuroxime 500 mg (child 3 months to 2 years: 10 mg/kg up to 125 mg; 2 years or older: 15 mg/kg up to 500 mg) orally, 12-hourly for 5 days
- doxycycline 100 mg (child 8 years or older: 2 mg/kg up to 100 mg) orally, 12-hourly for 5 days

# NON-ODONTOGENIC PAINS




Myocardial ischemia: insufficient blood flow and oxygen supply to the myocardium, usually due to narrowing or blockage of the coronary arteries from atherosclerosis.

- Imbalance between oxygen supply and myocardial demand leads to reversible cellular dysfunction and chest pain.

Provoked by physical exertion, emotional stress, cold exposure, heavy meals

Women > Men  
2:1

## Substernal Pain




Dull, aching, pressure-like, or crushing sensation

Radiates to left neck, shoulders, arms, epigastrium

Dyspnoea, diaphoresis, nausea, light-headedness, fatigue, sense of impending doom or anxiety


# PAIN OF CARDIAC ORIGIN



# PAIN OF CARDIAC ORIGIN

## CLINICAL PRESENTATION

Kreiner et al. J Oral Facial Pain Headache. 2014 Fall;28(4):317-21.



**38% have orofacial pain**  
Tooth (4%); mandible (45%);  
ear/TMJ (18%)

6% solely in  
orofacial region

Diagnostic local  
anaesthetic site of the  
painful tooth will not  
eliminate the pain

32% with  
coronary  
symptoms  
have pain in  
other areas

# PAIN OF CARDIAC ORIGIN MANAGEMENT

Immediate  
Emergency  
Medical  
Services  
Activation

Aspirin 300  
mg chewed  
immediately


Sublingual nitro-glycerine 0.4  
mg every 5 minutes  
(up to 3 doses)

Supplemental oxygen  
only if hypoxic (oxygen  
saturation <90%) or if  
patient is dyspnoeic or  
has signs of heart failure.

Routine oxygen therapy  
in normoxemic patients  
is NOT recommended  
and may cause harm.




# NON-ODONTOGENIC PAINS



# PAIN OF NEUROPATHIC ORIGIN



Neuropathic pain is pain that arises as a direct consequence of a lesion or diseases affecting the somatosensory system" IASP 2025



# TRIGEMINAL NEURALGIA



Brief, electric shock-like, lancinating pains that affects the face unilaterally affecting one or more divisions of the trigeminal nerve.



# TRIGEMINAL NEURALGIA


## CLINICAL PRESENTATION

### Diagnostic Criteria for Trigeminal Neuralgia

#### Diagnostic criteria

- |   |   |
|---|---|
| A | Recurrent paroxysms of the unilateral facial pain in the distribution(s) of one or more divisions of the trigeminal nerve, with no radiation beyond, and fulfilling criteria B and C  |
| B | Pain has all of the following characteristics: <ol style="list-style-type: none"><li>1. Lasting from a fraction of a second to 2 minutes</li><li>2. Severe intensity</li><li>3. Electric shock-like, shooting, stabbing or sharp in quality</li></ol> |
| C | <ol style="list-style-type: none"><li>1. Precipitated by innocuous stimuli within the affected trigeminal distribution</li></ol>  |
| D | Not better accounted by another ICHD-3 diagnosis  |

# TRIGEMINAL NEURALGIA CLINICAL PRESENTATION



Targeting the neurovascular contact: panel (a) is view of the right trigeminal root through the operating microscope. An arterial loop of the superior cerebellar artery has been lifted off the root. There is a band-like grayish discoloration of the root where it had been compressed close to its entrance to the brainstem. In panel (b), the picture is represented in diagrammatic form with the anatomical landmarks identified. (With permission from: Rappaport 2015)

# TRIGEMINAL NEURALGIA CLINICAL PRESENTATION



Secondary trigeminal neuralgia related to a schwannoma: heavily T2-weighted high-resolution axial (a) and T2-weighted fat-saturated coronal (b) MR images show a well-circumscribed ovoid nodule (arrow) in the left side of the pre-pontine cistern, inseparable from the cisternal segment of the left trigeminal nerve. Post-gadolinium T1 fat-saturated axial (c) image shows strong homogeneous enhancement of the mass (arrow). (Images courtesy of Dr Rudolf Boeddinghaus, Perth Radiological Clinic, Perth WA, Australia)

# TRIGEMINAL NEURALGIA MANAGEMENT

## DRUGS COMMONLY USED IN THE TREATMENT OF TRIGEMINAL NEURALGIA

Drug	Initial dose (mg)	Target dose (mg)*	Dose increase (titration)*	Schedule	Evidence†
Carbamazepine	100 to 200	1200	100 to 200 mg every 2 days	Three or four times per day	A
Carbamazepine controlled release	200 to 400	1200	Transferred from regular format at equivalent dose	Two times per day	A
Oxcarbazepine	300	1200 to 2400	300 to 600 mg/week	Three times per day	B
Baclofen	5 to 15	30 to 60	5 mg every 3 days	Three times per day	A
Gabapentin	300	900 to 2400	300 mg every 1 or 2 days	Three times per day	B
Pregabalin	150	300 to 600	50 mg every 2 or 3 days	Two or three times per day	
Lamotrigine	25	400 to 600	25 to 50 mg/week	One or two times per day	A‡

\*Titrate according to response and side effects.


†Evidence for efficacy rated A (best) or B (moderate).

‡Evidence for efficacy based on study using lamotrigine as add-in therapy.

# TRIGEMINAL NEURALGIA MANAGEMENT


*Just know there's surgical options*

ACUTE EPISODES OF TRIGEMINAL NEURALGIA	
Lignocaine	10mg spray, 5% ointment, 2% 1:80,000 adrenaline LA
Sumatriptan	6mg SC, 50mg twice daily (1 week)
Botulinum toxin A	Injection
Intravenous Infusions	Lignocaine, Phenytoin, Fosphenytoin






# PAIN OF NEUROPATHIC ORIGIN

Neuropathic pain is pain that arises as a direct consequence of a lesion or diseases affecting the somatosensory system"



Farah CS, Balasubramaniam R, McCullough MJ, eds. Contemporary Oral Medicine: A Comprehensive Approach to Clinical Practice. Springer; 2019.



## Risk Factors

- Macrotrauma
- Mandibular Third Molars
- Root Canal Treatment
- Local Anaesthetic Injections
- Blunt Macrotrauma
- "History of Trauma"


# POST-TRAUMATIC TRIGEMINAL NEUROPATHIC PAIN: CLINICAL PRESENTATION

## DIAGNOSTIC CRITERIA FOR POST-TRAUMATIC TRIGEMINAL NEUROPATHIC PAIN

### Criteria

A	Facial and/or oral pain in the distribution(s) of one or both trigeminal nerve(s) and fulfilling criterion C
B	History of an identifiable traumatic event to the trigeminal nerve(s), with clinically evident positive (hyperalgesia, allodynia) and/or negative (hypoesthesia, hypoalgesia) signs of trigeminal nerve dysfunction
C	Evidence of causation demonstrated by both of the following: <ol style="list-style-type: none"><li>1. Pain is localized to the distribution(s) of the trigeminal nerve(s) affected by the traumatic event</li><li>2. Pain has developed &lt;6 months after the traumatic event</li></ol>
D	Not better accounted by another ICHD-3 diagnosis

# POST-TRAUMATIC TRIGEMINAL NEUROPATHIC PAIN: MANAGEMENT



## PHARMACOTHERAPY

- Topical
- Systemic

## PSYCHOSOCIAL SUPPORT

- Cognitive Behavioural Therapy

## SURGERY

- CT-guided percutaneous trigeminal tractotomy-nucleotomy
- DREZ Surgery



# POST-TRAUMATIC TRIGEMINAL NEUROPATHIC PAIN: MANAGEMENT

## NEUROSENSORY STENT FOR TOPICAL MEDICATIONS



# POST-TRAUMATIC TRIGEMINAL NEUROPATHIC PAIN: MANAGEMENT

## SYSTEMIC MEDICATIONS

### Medical Status

- Tricyclic antidepressants
  - Amitriptyline
  - Nortriptyline
- Antiepileptic drugs
  - Gabapentin
  - Pregabalin

Combine Tricyclic Antidepressant & Antiepileptic drugs

Combine Serotonin and Noradrenaline Reuptake Inhibitors & Gabapentin

Combine Opioid & Gabapentin


Tramadol  
Opioids  
Naltrexone  
Botulinum Toxin  
Topical Applications  
(local anaesthetic, capsaicin, etc)

Ananthan S et al. Quintessence Int. 2025 Sep 18;56(8):682-690.

Park HJ et al. Biomedicines. 2024 Sep 10;12(9):2058.

Benoliel R, Sharav Y, editors. Orofacial Pain and Headache: A Comprehensive Guide. 3rd ed. Newcastle upon Tyne: Cambridge Scholars Publishing; 2024.

# NON-ODONTOGENIC PAINS




## ~~PSYCHOGENIC PAIN~~

**Somatic Symptom Disorder:** presence of one or more somatic symptoms that cause distress or significant disruption to daily life, characterised by excessive thoughts, behaviour, or feelings related to the symptoms or health concerns.

- ~~“Functional Somatic Syndrome”~~
- **Caution:** A failure on the part of the clinician to diagnose, should not lead to a “default” diagnosis of somatoform pain disorder.



# SOMATIC SYMPTOM DISORDER



# SOMATIC SYMPTOM DISORDER

## Diagnostic criteria:

- A. One or more somatic symptoms that are distressing or result in significant disruption of daily life.
- B. Excessive thoughts, feelings, or behaviors related to the somatic symptoms or associated health concerns as manifested by at least one of the following:
  1. Disproportionate and persistent thoughts about the seriousness of one's symptoms.
  2. Persistently high level of anxiety about health or symptoms.
  3. Excessive time and energy devoted to these symptoms or health concerns.
- C. Although any one somatic symptom may not be continuously present, the state of being symptomatic is persistent (typically more than 6 months).

## *Specify if:*

With predominant pain (previously pain disorder): This specifier is for individuals whose somatic symptoms predominantly involve pain.

## *Specify if:*

Persistent: A persistent course is characterized by severe symptoms, marked impairment, and long duration (more than 6 months).

## *Specify current severity:*

Mild: Only one of the symptoms specified in Criterion B is fulfilled.

Moderate: Two or more of the symptoms specified in Criterion B are fulfilled.

Severe: Two or more of the symptoms specified in Criterion B are fulfilled, plus there are multiple somatic complaints (or one very severe somatic symptom).

# SOMATIC SYMPTOM DISORDER CLINICAL PRESENTATION

- Pain descriptors often diffuse, vague and difficult to localise
- Multiple teeth often involved, with frequent change in character and location
- Inconsistent with physiological pain and present without any identifiable pathological cause
- Chronic pain behaviour
- Lack of response to reasonable dental treatment
- Unusual or unexpected response to therapy

# SOMATIC SYMPTOM DISORDER MANAGEMENT

## Regular Consultations

- Schedule short-interval follow-up to stop overuse of medical care
- stress coping rather than cure

## Empathy

- Spend most of the time listening to the patient and acknowledge that what he or she is feeling is real

## Mind-Body Interface

- Emphasize the mind-body connection; avoid comments such as “there is nothing medically wrong with you”

## REFER TO PSYCHIATRIST

- 90% have persistent symptoms at 5 years follow-up


# SOMATIC SYMPTOM DISORDER MANAGEMENT

## REFER TO A PSYCHIATRIST (Kurlansik SL, Maffei MS. Am Fam Physician. 2016 Jan 1;93(1):49-54.)

Modality	Evidence	Findings
Cognitive Behavioural Therapy	Multicenter randomised controlled trial, reviews of controlled clinical trials	Effective for treatment of somatic symptom disorder and medically unexplained symptoms "Health anxious" patients had sustained symptomatic benefit over two years, with no significant effect on total costs. Reduced physical symptoms, psychological distress, and disability.
Mindfulness-Based Therapy	Meta-analysis of randomised controlled trials	May be effective in treating some aspects of somatic symptom disorder. Significant and sustained improvements in clinical outcomes (overall symptom severity, depression, and anxiety) compared with control groups.
Pharmacotherapy	Systematic reviews of controlled trials	<b>Amitriptyline</b> shows benefit for one or more of the following outcomes: fatigue, functional symptoms, global improvement, morning stiffness, pain, sleep, and tender points. <b>Fluoxetine</b> shows benefit for functional status, global well-being, morning stiffness, pain, sleep, and tender points. Monoamine oxidase inhibitors, bupropion, antiepileptics, and antipsychotics showed no benefit and should not be used.
St. John's Wort	Randomised, double-blind, placebo-controlled trials (lower-quality studies)	More effective than placebo for improvement in self-reported somatic symptoms; well-tolerated and safe

# NON-ODONTOGENIC PAINS

Miscellaneous



# NON-ODONTOGENIC TOOTHACHES: MISCELLANEOUS



rs12411980 SNP  
related  
to *PRTFDC1* expression



**Diabetes**



**Sickle Cell  
Disease**



**Menstrual  
Cycle**



**Chemotherapy-  
Induced  
Toxicity**



**Infections**



**Vertebral Artery  
Pseudoaneurysm**



**Burkitt's  
Lymphoma**



**Barodontalgia**



**Giant Cell  
Arteritis**



ODONTOGENIC PAINS


SITE VS SOURCE OF OROFACIAL PAIN

NON-ODONTOGENIC PAINS


TAKE HOME MESSAGE




# TAKE HOME MESSAGE




Toothache  $\neq$  Odontogenic Pain



Site of Pain  $\neq$  Source of Pain



Appreciate the various aetiologies of non-odontogenic toothaches



Early diagnosis of non-odontogenic toothache avoids unnecessary dental treatments

RB

THANK YOU

Ramesh Balasubramaniam OAM

